Company Monitoring Page for Clovis-Oncology

latest headlines for company on cafepharma

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
Tue, 06/27/17 - 09:45 am
Tags:
AbbVie, biosimilars, Humira, Clovis Oncology, Rubraca, Novartis, Regeneron, Eylea
Is Clovis Oncology A Takeover Candidate?
Seeking Alpha
Mon, 06/26/17 - 04:54 pm
Tags:
Clovis Oncology, M&A, rucaparib, PARP inhibitors
Look for Clovis Oncology to Resume Its Advance
TheStreet.com
Mon, 03/20/17 - 11:19 pm
Tags:
Clovis Oncology
Clovis, Tesaro Soar on Astrazeneca Phase Three News
TheStreet.com
Sat, 02/18/17 - 02:37 pm
Tags:
Clovis Oncology, Tesaro, AstraZeneca, clinical trials, Lynparza, breast cancer
3 Biotechs Likely to Be Acquired in 2017
Motley Fool
Mon, 01/23/17 - 10:18 am
Tags:
M&A, Clovis Oncology, Intercept Pharma, Jazz Pharmaceuticals
Biotech Stocks: What to Watch in 2017
Motley Fool
Sun, 01/1/17 - 11:33 am
Tags:
biotech, Seattle Genetics, Exelixis, Clovis Oncology, Kite Pharma
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
TheStreet.com
Mon, 12/19/16 - 11:51 am
Tags:
Clovis Oncology, FDA, PARP inhibitors, rucaparib, ovarian cancer, Rubraca
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
Sun, 12/4/16 - 12:37 pm
Tags:
biotech, Alnylam, revusiran, Clovis Oncology, rociletinib, Celldex Therapeutics, Rintega, Eli Lilly, solanezumab, Novavax, RSV-F, Arrowhead, ARC-520, ARC-521, ARC-AAT, Biomarin, drisapersen
3 Cancer Drugs That Could Get an FDA OK Next Year
Motley Fool
Mon, 10/10/16 - 09:02 am
Tags:
FDA, rucaparib, Clovis Oncology, ovarian cancer, binimetinib, Array Biopharma, melanoma, brigatinib, Ariad Pharmaceuticals, non-small cell lung cancer
Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition
TheStreet.com
Fri, 10/7/16 - 04:55 pm
Tags:
Clovis Oncology, ovarian cancer, rucaparib, Lynparza, AstraZeneca
3 Biotechs That Could Be M&A Targets
Motley Fool
Sat, 09/24/16 - 01:40 pm
Tags:
biotech, M&A, cancer, Seattle Genetics, Array Biopharma, Clovis Oncology
Takeover Chatter Around Clovis May Be Overdone
TheStreet.com
Fri, 09/23/16 - 10:10 pm
Tags:
Clovis Oncology, M&A, Eli Lilly, Merck, Takeda
Clovis soars on FDA decision to bypass panel for cancer candidate
Fierce Biotech
Fri, 09/9/16 - 10:24 am
Tags:
Clovis Oncology, FDA, advisory panels, rucaparib, ovarian cancer
Clovis Jumps as Cancer Drug Gets Priority for FDA Review
Bloomberg
Tue, 08/23/16 - 05:47 pm
Tags:
Clovis Oncology, FDA, priority review, rucaparib, ovarian cancer
3 Shocking Biotech Flops of 2016 So Far
Motley Fool
Fri, 07/8/16 - 11:01 am
Tags:
biotech, Rintega, Celldex Therapeutics, glioblastoma, Clovis Oncology, rociletinib, lung cancer, NewLink Genetics, algenpantucel-L, pancreatic cancer
An Overnight Double! Could These Drugmakers Be Next?
Motley Fool
Sat, 07/2/16 - 12:36 pm
Tags:
Tesaro, ovarian cancer, PARP inhibitors, niraparib, AstraZeneca, Lynparza, Medivation, AbbVie, Clovis Oncology
These 15 Biotech Companies Could Be Takeover Targets
Barron's
Wed, 06/29/16 - 12:56 pm
Tags:
biotech, M&A, Alder Biopharmaceuticals, Biomarin, Coherus Biosciences, Intercept Pharma, Ultragenyx, Seattle Genetics, Adamas Pharmaceuticals, Alexion, Clovis Oncology, Corbus Pharmaceuticals, Incyte, Prothena, Puma Biotechnology, Tesaro, Versartis
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
Yahoo
Mon, 06/6/16 - 11:04 am
Tags:
Clovis Oncology, rucaparib, ovarian cancer, pancreatic cancer, ASCO 2016
2 FDA Decisions To Watch In June
Seeking Alpha
Wed, 06/1/16 - 10:54 am
Tags:
FDA, rociletinib, Clovis Oncology, KemPharm, Apadaz
After shutting down cancer drug, Clovis now facing government investigations
BioPharma Dive
Fri, 05/13/16 - 10:15 am
Tags:
Clovis Oncology, rociletinib, FDA

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.